Loading…
No QTc prolongation with CDK 4/6 inhibitor FCN-437c: results of a concentration-QTc analysis from a dedicated study in adult healthy subjects
Zhao, Lin, Sun, Yi, Yang, Xiaoran, Tian, Ling, Li, Lize, Wang, Fangfang, Niu, Xiaoye, Diao, Lei, Li, Haiyan
Published in Frontiers in pharmacology (12.08.2024)
Published in Frontiers in pharmacology (12.08.2024)
Get full text
Journal Article
Loading…
A phase I clinical trial investigating the safety, tolerability, and pharmacokinetics of HX301 (narazaciclib), a novel multi-kinase inhibitor targeting CSF1R, CDK 4/6, and ARK5, in patients with advanced solid tumors
Shi, Yehui, Luo, Suxia, Li, Qing, Zhang, Faming, Zhang, Lei, Sun, Peng, Mo, Yunlong, Yu, Ting, Xu, Binghe
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
Loading…
SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27
Carrano, Andrea C., Eytan, Esther, Hershko, Avram, Pagano, Michele
Published in Nature cell biology (01.08.1999)
Published in Nature cell biology (01.08.1999)
Get full text
Journal Article
Loading…
3100 Phase Ib/II study of the pan-cyclin-dependent kinase (CDK) inhibitor roniciclib (BAY 1000394) in combination with chemotherapy as first-line therapy in subjects with extensive disease small cell lung cancer (ED-SCLC)
Cho, B.C., Dy, G.K., Govindan, R., Kim, D.W., Pennell, N.A., Zalcman, G., Besse, B., Nogai, H., Rajagopalan, P., Ocker, M., Barlesi, F.
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
Loading…
Abstract P1-14-02: Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER, part 1)
Spring, Laura M, Scarpetti, Lauren, Niemierko, Andrzej, Isakoff, Steven J, Moy, Beverly, Wander, Seth A, Smith, Elisabeth, Abraham, Elizabeth, Shin, Jennifer, Patel, Jaymin M, Comander, Amy, Mulvey, Therese, Bardia, Aditya
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Get full text
Journal Article
Loading…
Vascular inflammation and cardiovascular burden in metastatic breast cancer female patients receiving hormonal treatment and CDK 4/6 inhibitors or everolimus
Papageorgiou, C, Zagouri, F, Dimopoulos, M, Manios, E, Kafouris, P, Tousoulis, D, Anagnostopoulos, C, Toutouzas, K
Published in European heart journal (01.11.2020)
Published in European heart journal (01.11.2020)
Get full text
Journal Article
Loading…
Abstract OT2-17-01: Randomized, multicenter, international phase 3 ARTEST study to evaluate the efficacy and safety of enobosarm versus active control for the treatment of AR+ ER+ HER2- metastatic breast cancer in patients who progressed on a nonsteroidal aromatase inhibitor, fulvestrant and CDK 4/6 inhibitor
Brufsky, Adam, Linden, Hannah, Rugo, Hope, Vogel, Charles, O'Shaughnessy, Joyce A, Getzenberg, Robert H, Barnette, K. Gary, Rodriguez, Domingo, Steiner, Mitchell S, Mayer, Erica
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Get full text
Journal Article
Loading…
EPCT-05. A PHASE I TRIAL OF THE CDK 4/6 INHIBITOR PALBOCICLIB IN PEDIATRIC PATIENTS WITH PROGRESSIVE OR REFRACTORY CNS TUMORS: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY
Van Mater, David, Gururangan, Sridharan, Leary, Sarah, Becher, Oren, Phillips, Joanna, Huang, Jie, Campagne, Olivia, Poussaint, Tina, Goldman, Stewart, Baxter, Patricia, Dhall, Girish, Robinson, Giles, DeWire-Schottmiller, Mariko, Hwang, Eugene, Stewart, Clinton, Onar-Thomas, Arzu, Dunkel, Ira, Fouladi, Maryam
Published in Neuro-oncology (Charlottesville, Va.) (04.12.2020)
Published in Neuro-oncology (Charlottesville, Va.) (04.12.2020)
Get full text
Journal Article
Loading…
Cdk-mediated phosphorylation of Chk1 is required for efficient activation and full checkpoint proficiency in response to DNA damage
Xu, N, Libertini, S, Black, E J, Lao, Y, Hegarat, N, Walker, M, Gillespie, D A
Published in Oncogene (01.03.2012)
Published in Oncogene (01.03.2012)
Get full text
Journal Article
Loading…
Abstract 2835: Voruciclib, a clinical stage oral CDK inhibitor, sensitizes triple negative breast cancer xenografts to proteasome inhibition
Dey, Joyoti, Casalini, Joseph, Ditzler, Sally, Biery, Matt, Merrell, Angela, Thirstrup, Derek, Grenley, Marc, Klinghoffer, Richard
Published in Cancer research (Chicago, Ill.) (15.07.2016)
Published in Cancer research (Chicago, Ill.) (15.07.2016)
Get full text
Journal Article
Loading…
Abstract OT1-05-01: A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor, in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer
Santa-Maria, CA, Rampurwala, M, Wisinski, K, Toppmeyer, D, O'Regan, R
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Get full text
Journal Article
Loading…
Prediction of therapeutic outcome and survival in a transgenic mouse model of pancreatic ductal adenocarcinoma treated with dendritic cell vaccination or CDK inhibitor using MRI texture: a feasibility study
Eresen, Aydin, Yang, Jia, Shangguan, Junjie, Li, Yu, Hu, Su, Sun, Chong, Yaghmai, Vahid, Benson Iii, Al B, Zhang, Zhuoli
Published in American journal of translational research (01.01.2020)
Get full text
Published in American journal of translational research (01.01.2020)
Journal Article
Loading…
Abstract OT2-01-02: The SMILE Study: A phase II trial of onapristone in combination with fulvestrant for patients with ER-positive and HER2-negative metastatic breast cancer after progression on endocrine therapy and CDK 4/6 inhibitors
Kamaraju, Sailaja, Fowler, Amy, Chaudhary, Lubna N., Burkard, Mark, Giever, Thomas, Hegeman, Robert N, Pipp-Dahm, Michele, Cheng, Yee Chung, Lange, Carol, Jorns, Julie M., Stella, Amy, Siddiqui, Nauman, Zurbriggen, Luke, Rajguru, Saurabh, Tarima, Sergey, Sriram, Deepika, Retseck, Janet, Rui, Hallgeir, Sahmoud, Tarek, Wisinski, Kari B.
Published in Cancer research (Chicago, Ill.) (01.03.2023)
Published in Cancer research (Chicago, Ill.) (01.03.2023)
Get full text
Journal Article
Loading…
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Chronic Lymphocytic Leukemia: NCIC CTG Trial IND.193
Seftel, Matthew D., Kuruvilla, John, Banerji, Versha, Fraser, Graeme, Xu, Hao, Powers, Jean, Crocker, Susan, Toguchi, Marcia, Lyons, John F, Seymour, Lesley, Hay, Annette E
Published in Blood (06.12.2014)
Published in Blood (06.12.2014)
Get full text
Journal Article
Loading…
The impact of senescence on muscle wasting in chronic kidney disease
Huang, Ying, Wang, Bin, Hassounah, Faten, Price, S. Russ, Klein, Janet, Mohamed, Tamer M.A., Wang, Yanhua, Park, Jeanie, Cai, Hui, Zhang, Xuemei, Wang, Xiaonan H.
Published in Journal of cachexia, sarcopenia and muscle (01.02.2023)
Published in Journal of cachexia, sarcopenia and muscle (01.02.2023)
Get full text
Journal Article
Loading…
AB0529 Rituximab therapy monitoring by mtor, autophagy-related ULK1, caspase 3, CDK-inhibitor P21, TNF alpha, and osteoclast-specific cathepsin K and gelatinase MMP-9 gene expression in the peripheral blood of rheumatoid arthritis patients
Tchetina, E.V., Kuzikyants, K.H., Devyataikina, A.Y., Lukina, G.V., Nasonov, E.L.
Published in Annals of the rheumatic diseases (01.06.2013)
Published in Annals of the rheumatic diseases (01.06.2013)
Get full text
Journal Article
Loading…
AB0276 Methotrexate therapy monitoring by MTOR, autophagy-related ULK1, caspase 3, CDK-inhibitor p21, TNF alpha, and osteoclast-specific cathepsin K and gelatinase MMP-9 gene expression in the peripheral blood of early rheumatoid arthritis patients
Tchetina, E.V., Demidova, N.V., Karateev, D.E., Nasonov, E.L.
Published in Annals of the rheumatic diseases (01.06.2013)
Published in Annals of the rheumatic diseases (01.06.2013)
Get full text
Journal Article
Loading…
Cdk
Published in Oxford Dictionary of Biochemistry and Molecular Biology
(01.01.2006)
Get full text
Reference
Loading…
Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL)
Flynn, Joseph M.M., Andritsos, Leslie A., Jones, Jeffrey A., Johnson, Amy J., Maddocks, Kami, Wiley, Elizabeth, Small, Karen, Im, Eun Kyung, Grever, Michael R., Bannerji, Rajat, Byrd, John C., Zhou, Honghong
Published in Blood (15.11.2013)
Published in Blood (15.11.2013)
Get full text
Journal Article